Renovacor’s mission is to deliver innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases.
Our lead program is a recombinant adeno-associated virus (AAV9)‑based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the Bcl2‑associated athanogene 3 (BAG3) gene. BAG3-associated DCM pat...
Renovacor’s mission is to deliver innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases.
Our lead program is a recombinant adeno-associated virus (AAV9)‑based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the Bcl2‑associated athanogene 3 (BAG3) gene. BAG3-associated DCM patients tend to be relatively young, with an average age at diagnosis of 37 years.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.